Efficacy and Safety of Clonidine Transdermal Patch for Child Tic Disorders ：A Meta-analysis
- VernacularTitle:可乐定透皮贴治疗儿童抽动障碍的有效性与安全性的Meta分析
- Author:
Haoxin SONG
1
,
2
,
3
,
4
;
Zongyao HUANG
1
,
2
,
3
,
4
;
Chunsong YANG
2
,
3
,
4
;
Dan YU
5
;
Lingli ZHANG
2
,
3
,
4
;
Xuehua JIANG
1
Author Information
1. West China School of Pharmacy，Sichuan University，Chengdu 610041，China
2. Dept. of Pharmacy，West China Second University Hospital，Sichuan University，Chengdu 610041，China
3. Evidence-based Pharmacy Center，West China Second University Hospital，Sichuan University，Chengdu 610041，China
4. Key Laboratory of Birth Defects and Related Diseases of Women and Children （Sichuan University ），Ministry of Education，Chengdu 610041，China
5. Dept. of Pediatrics，West China Second University Hospital，Sichuan University，Chengdu 610041，China
- Publication Type:Journal Article
- Keywords:
Clonidine;
Transdermal patch;
Children;
Tic disorder;
Meta-analysis
- From:
China Pharmacy
2019;30(1):125-130
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE： To systematically evaluate the efficacy and safety of Clonidine tansdermal patch for child tic disorders in children， and to provide evidence-based reference for clinical treatment. METHODS： Retrieved from Medline， Embase， Cochrane library， CNKI， VIP， CBM and Wanfang database， randomized controlled trials （RCTs） about Clonidine tansdermal patch （trial group） versus other therapies （control group， including placebo group， thiopride group， haloperidol group） for child tic disorders were collected from datbase estallishment to July 2018. The literatures met inclusion criteria were summarized. After quality evaluation with Cochrane system evaluation manual 5.1.0， Meta-analysis of reduction rate （amount） of YGTSS， the incidence of ADR and response rate was performed by using Rev Man 5.3 statistical software. Descriptive analysis was performed on indicators of groups that were unable to perform Meta-analysis. RESULTS： A total of 8 RCTs involving 1 320 patients were included. Among them， 2 RCTs involved placebo in control group； 2 RCTs involved thiopride， 3 RCTs involved haloperidol， and 1 RCT involved thiopride and haloperidol. Results of Meta-analysis showed that reduction rate of YGTSS in trial group were significantly higher than haloperidol group [MD＝21.94， 95％CI（21.03， 22.86）， P＜0.001]， but there was no statistical significance compared with thiopride group [MD＝10.66， 95％CI（－15.68， 37.00）， P＝0.43]. The incidence of adverse events （mainly including skin itching， redness， dry mouth， dizziness， decreased blood pressure， abnormal electrocardiogram） in trial group were significantly lower than thiopride group [OR＝0.42， 95％CI（0.22， 0.82）， P＝0.01] and haloperidol group [OR＝0.17， 95％CI（0.09， 0.32）， P＜0.001]， but there was no statistical significance compared with placebo group [OR＝0.61， 95％CI（0.29， 1.29）， P＝0.20]. There was no statistical significance in response rate of trial group compared with thiopride group [OR＝1.29，95％CI（0.38， 4.39）， P＝0.69] and haloperidol group [OR＝1.63， 95％CI（0.89， 2.96）， P＝0.11]. The results of descriptive analysis showed that reduction rate （amount） of YGTSS in trial group was significantly higher than that of placebo group （P＜0.05）， and response rate of trial group was significantly higher than that of placebo group （P＜0.01）. CONCLUSIONS： For child tic disorders in children， Clonidine tansdermal patch is better than placebo and haloperidol in reduction rate （amount） of YGTSS， and is similar to thiopride. Response rate of Clonidine tansdermal patch is better than that of placebo， and is similar to those of thiopride and haloperidol. The safety of Clonidine tansdermal patch is better than those of thiopride and haloperidol， and is similar to that of placebo.
